[go: up one dir, main page]

WO2013058527A3 - Formulation combinée d'un antagoniste de leucotriène et de l'épinastine - Google Patents

Formulation combinée d'un antagoniste de leucotriène et de l'épinastine Download PDF

Info

Publication number
WO2013058527A3
WO2013058527A3 PCT/KR2012/008458 KR2012008458W WO2013058527A3 WO 2013058527 A3 WO2013058527 A3 WO 2013058527A3 KR 2012008458 W KR2012008458 W KR 2012008458W WO 2013058527 A3 WO2013058527 A3 WO 2013058527A3
Authority
WO
WIPO (PCT)
Prior art keywords
epinastine
leukotriene antagonist
combined formulation
active ingredients
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/008458
Other languages
English (en)
Korean (ko)
Other versions
WO2013058527A2 (fr
Inventor
이창규
박상근
최현주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navipharm Co Ltd
Original Assignee
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120069220A external-priority patent/KR101278572B1/ko
Application filed by Navipharm Co Ltd filed Critical Navipharm Co Ltd
Priority to CN201280051128.XA priority Critical patent/CN103889424A/zh
Publication of WO2013058527A2 publication Critical patent/WO2013058527A2/fr
Publication of WO2013058527A3 publication Critical patent/WO2013058527A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation combinée d'un antagoniste de leucotriène et de l'épinastine qui contient un antagoniste de leucotriène et de l'épinastine en tant que principes actifs, qui comporte une unité pharmaceutique, l'un quelconque des deux principes actifs ayant un environnement séparé de celui de l'autre. L'invention concerne également le procédé de préparation de ladite formulation. La formulation combinée présente d'excellentes caractéristiques en termes de vitesse de dissolution et de biodisponibilité d'un antagoniste de leucotriène. De plus, les deux principes actifs réduisent de façon synergique la quantité d'éosinophiles ou inhibent l'hypersensibilité des voies respiratoires rendant ainsi la formulation combinée très utile pour la prévention ou le traitement de l'asthme.
PCT/KR2012/008458 2011-10-18 2012-10-17 Formulation combinée d'un antagoniste de leucotriène et de l'épinastine Ceased WO2013058527A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280051128.XA CN103889424A (zh) 2011-10-18 2012-10-17 白三烯拮抗剂和依匹斯汀的复合制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110106382 2011-10-18
KR10-2011-0106382 2011-10-18
KR10-2012-0069220 2012-06-27
KR1020120069220A KR101278572B1 (ko) 2011-10-18 2012-06-27 류코트리엔 길항제와 에피나스틴의 복합제제

Publications (2)

Publication Number Publication Date
WO2013058527A2 WO2013058527A2 (fr) 2013-04-25
WO2013058527A3 true WO2013058527A3 (fr) 2013-06-20

Family

ID=48141524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008458 Ceased WO2013058527A2 (fr) 2011-10-18 2012-10-17 Formulation combinée d'un antagoniste de leucotriène et de l'épinastine

Country Status (1)

Country Link
WO (1) WO2013058527A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
CN103251563A (zh) * 2013-05-22 2013-08-21 北京科源创欣科技有限公司 依匹斯汀或其盐酸盐的稳定的颗粒状药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100737710B1 (ko) * 1997-12-23 2007-07-11 쉐링 코포레이션 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물
KR20080016621A (ko) * 2005-06-09 2008-02-21 바이올리폭스 에이비 염증성 질병 치료용 조성물 및 방법
KR20090103810A (ko) * 2008-03-28 2009-10-01 코와 가부시키가이샤 정제
US20110189274A1 (en) * 2008-10-06 2011-08-04 Swati Mukherjee Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100737710B1 (ko) * 1997-12-23 2007-07-11 쉐링 코포레이션 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물
KR20080016621A (ko) * 2005-06-09 2008-02-21 바이올리폭스 에이비 염증성 질병 치료용 조성물 및 방법
KR20090103810A (ko) * 2008-03-28 2009-10-01 코와 가부시키가이샤 정제
US20110189274A1 (en) * 2008-10-06 2011-08-04 Swati Mukherjee Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALISE REICIN ET AL.: "Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma", ARCHIVES INTERNAL MEDICINE, vol. 160, 2000, pages 2481 - 2488 *

Also Published As

Publication number Publication date
WO2013058527A2 (fr) 2013-04-25

Similar Documents

Publication Publication Date Title
WO2012021715A3 (fr) Formulations stables de linaclotide
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
WO2012078593A3 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
WO2011086531A3 (fr) Nouveaux agents antipaludiques
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
WO2011157722A3 (fr) Composition contenant de l'ivabradine solide
WO2013055689A8 (fr) R(+)-n-méthyl-propargyl-aminoindane
WO2013055684A8 (fr) Citramide de rasagiline
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
WO2012101653A3 (fr) Compositions pharmaceutiques de mémantine à libération modifiée
WO2012001705A3 (fr) Compositions pharmaceutiques de (r)-lansoprazole
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
WO2012019428A8 (fr) Dérivés de benzohydrol, procédé de préparation et utilisation pharmaceutique de ceux-ci
WO2012155226A8 (fr) Procédé pour la production de dérivés de pyrostegia venusta, dérivés de pyrostegia venusta, compositions pharmaceutiques et leurs utilisations
EP2722322B8 (fr) Dérivé de 1,3-di-oxo-indène, son isomère optique ou son sel pharmaceutiquement acceptable, son procédé de préparation, et composition pharmaceutique le contenant en tant que principe actif antiviral
WO2013058527A3 (fr) Formulation combinée d'un antagoniste de leucotriène et de l'épinastine
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir
WO2013188279A8 (fr) Composition pharmaceutique ophtalmique topique contenant du cediranib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12841792

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014536980

Country of ref document: JP

Kind code of ref document: A

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/08/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12841792

Country of ref document: EP

Kind code of ref document: A2